Company

Immunic Therapeutics

Rocket Ship Rating

Rocket Ship Rating: 98 out of 100

Developing Selective Oral Drugs in Immunology

Also known as Immunic, Inc.

Biotech & therapeutics

Status: IPOas of 2026-09-17Source (opens in a new tab)
Business model: B2B
Headquarters: New York City, NY, United States
Founded: 2016
Legal name: Immunic, Inc.

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases

Funding snapshot

Total raised: $514MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Round, $200M2026-02-17

Funding rounds

Round, 2026: $200M2026-02-17, SEC form D sold, 43 investors
Round, 2024: $80M2024-01-04, SEC form D sold, 19 investors
Round, 2022: $60M2022-10-10, SEC form D sold, 14 investors
Round, 2014: $13.9M2014-01-24, SEC form D sold, 37 investors
Round, 2013: $32M2013-02-28, SEC form D sold, 62 investors
Round, 2012: $86.1M2012-09-25, SEC form D sold, 40 investors
Round, 2012: $2.5M2012-05-14, SEC form D sold, 1 investor
Round, 2012: $930K2012-02-03, SEC form D sold, 7 investors
Round, 2011: $22.6M2011-05-19, SEC form D sold, 51 investors
Round, 2009: $16.3M2009-09-25, SEC form D sold, 42 investors

About the company

Status notes: has been trading on the Nasdaq Stock Market under the ticker symbol ”IMUX.”